Compare Amgen, Inc. (AMGN) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Keysight Technologies Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Keysight Technologies Inc trades at $327 (market cap $55.04B). The key difference: Amgen, Inc. is far larger — about 3.6× Keysight Technologies Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| AMGN | KEYS | |
|---|---|---|
Market Cap | $196.12B | $55.04B |
Sector | Health | Technology |
52-Week High | $388.16 | $373.34 |
52-Week Low | $271.18 | $158.51 |
Enterprise Value | $241.41B | $55.38B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KEYS trades at $322.05, down 0.04% on the day, with a bearish technical signal despite strong fundamentals. The company reported revenue of $5.38B in 2025 with net income of $850M, and has beaten EPS estimates for three consecutive quarters. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Outlook remains positive with 75% analyst buy ratings and a $390.30 consensus price target, implying 21% upside. Key risks include high valuation multiples and volatile cash flows from significant investing activities. Earnings growth driven by technology demand presents the primary investment opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
